24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Completed · Phase 3 · Has a placebo group

Conditions studied: Hot Flashes

In brief

To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause

Key facts

Study ID
NCT01101841
Run by
Noven Therapeutics
People needed
570
Starts
2010-03-01
Expected to finish
2011-11-01
Last updated by the study team
2015-10-15

Who can join

Age: 40 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.